CAMBREX has announced the expansion of its solid form screening and crystallization process development facility in Edinburgh. The expansion project has seen its facility double in size to15,000 square feet, with a refurbishment of its lab, and an additional 3,500 square feet of laboratory space added.
Tom Loewald, Chief Executive Officer of Cambrex said: “We have seen an increase in demand for services, and specifically for larger-scale crystallization projects, so this expansion increases our efficiency and ability to respond to these requests. The work we carry out at the Edinburgh site is one part of Cambrex’s integrated drug substance offering, and the investment increases our flexibility to work on projects at all stages of drug development.”
Cambrex’s Edinburgh site is a world-class facility, providing solid form development services for drug substance and drug product. These include solid state investigations such as salt, co-crystal, and polymorph screening, in addition to crystallization process development and GMP analytical services. Cambrex’s expert scientists offer standalone project work for pharmaceutical innovators as well as integrated services.
The expansion and refurbishment of the lab include an additional 13 fume cupboards, three of which are “walk-in”, which will increase capacity and provide clients with crystallization development, up to a 20-liter scale. The expansion will add additional laboratory space to recruit 40 scientists, who would join Cambrex’s team of 50 employees, with the potential for further growth in the future.
Cambrex is a leading small molecule company that provides drug substance, drug product, and analytical services across the entire drug lifecycle. The company provides customers with an end-to-end partnership for the research, development, and manufacture of small molecule therapeutics. With over 35 years’ experience and a growing team of over 2,100 experts servicing global clients from sites in North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and dosage form development and manufacturing.